COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has acquired an intellectual property (IP) portfolio including patent applications covering a variety of psychedelic and empathogenic substances. The IP was developed together with inventor Matthias Grill PhD…

Source

Previous articlePharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022
Next articlePT262 – Carlene MacMillan, M.D. – Set, Setting, and Systems: Adding Insurance to the Conversation